Protein Summary
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DN ...more
- ENST00000266970
- ENSP00000266970
- ENSG00000123374
- ENST00000354056
- ENSP00000243067
- CDKN2
- CDKN2
- p33(CDK2)
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
chemical | 1 | ||
drug perturbation | 1 | ||
hub protein | 1 | ||
biological process | 0.99 | ||
biological term | 0.99 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3206.11 (req: < 5)
Gene RIFs: 360 (req: <= 3)
Antibodies: 1544 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3206.11 (req: >= 5)
Gene RIFs: 360 (req: > 3)
Antibodies: 1544 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 31
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 479
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3